NASD · Healthcare · Diagnostics & Research · USA
Insight Molecular Diagnostics Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.
Insight Molecular Diagnostics develops molecular diagnostic test kits for transplant organ rejection monitoring and oncology. The company operates a CLIA-certified laboratory in Tennessee and serves hospitals, transplant centers, and research institutions through laboratory tests and in-house kitted products. Its GraftAssure family of assays measures donor-derived cell-free DNA and includes a Medicare-reimbursed laboratory test and research kits.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Insight Molecular Diagnostics Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
All 44 Diagnostics & Research stocks
23 more in this industry show a wider margin of safety.
We do not publish a verdict on IMDX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.